These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29113203)

  • 41. Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer.
    Yamaguchi T; Iwasa S; Shoji H; Honma Y; Takashima A; Kato K; Hamaguchi T; Higuchi K; Boku N
    Gastric Cancer; 2019 Jul; 22(4):778-784. PubMed ID: 30603911
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B).
    Fukuda M; Suetsugu T; Shimada M; Kitazaki T; Hashiguchi K; Kishimoto J; Harada T; Seto T; Ebi N; Takayama K; Sugio K; Semba H; Nakanishi Y; Ichinose Y
    Thorac Cancer; 2016 Jul; 7(4):467-72. PubMed ID: 27385990
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity.
    Kitagawa C; Ando M; Ando Y; Sekido Y; Wakai K; Imaizumi K; Shimokata K; Hasegawa Y
    Pharmacogenet Genomics; 2005 Jan; 15(1):35-41. PubMed ID: 15864124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
    Biason P; Masier S; Toffoli G
    J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Study on the Optimal Dose of Irinotecan for Patients with Heterozygous Uridine Diphosphate-Glucuronosyltransferase 1A1 (UGT1A1).
    Konaka K; Sakurada T; Saito T; Mori S; Imanishi M; Kakiuchi S; Fushitani S; Ishizawa K
    Biol Pharm Bull; 2019; 42(11):1839-1845. PubMed ID: 31685767
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacogenetics and irinotecan therapy.
    Hahn KK; Wolff JJ; Kolesar JM
    Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).
    Fukuda M; Shimada M; Kitazaki T; Nagashima S; Hashiguchi K; Ebi N; Takayama K; Nakanishi Y; Semba H; Harada T; Seto T; Okamoto I; Ichinose Y; Sugio K
    Thorac Cancer; 2017 Jan; 8(1):40-45. PubMed ID: 27883280
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction].
    Onoue M; Inui K
    Gan To Kagaku Ryoho; 2008 Jul; 35(7):1080-5. PubMed ID: 18633245
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan-based chemotherapy in Chinese populations.
    Ma X; Han S; Liu Y; Liu JT; Fang J; Zhang YH
    J Pharm Pharmacol; 2020 Nov; 72(11):1528-1535. PubMed ID: 32737884
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism.
    Jannin A; Hennart B; Adenis A; Chauffert B; Penel N
    Case Rep Oncol Med; 2017; 2017():2683478. PubMed ID: 29098099
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Detection of UGT1A1*28 Polymorphism Using Fragment Analysis].
    Huang Y; Su J; Huang X; Lu D; Xie Z; Yang S; Guo W; Lv Z; Wu H; Zhang X
    Zhongguo Fei Ai Za Zhi; 2017 Dec; 20(12):817-821. PubMed ID: 29277179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
    Park SR; Kong SY; Rhee J; Park YI; Ryu KW; Lee JH; Kim YW; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim NK
    Ann Oncol; 2011 Apr; 22(4):890-896. PubMed ID: 20860988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.
    Xu Q; Ding YY; Song LX; Xu JF
    Genet Mol Res; 2015 Jun; 14(2):7241-7. PubMed ID: 26125934
    [TBL] [Abstract][Full Text] [Related]  

  • 54. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
    Ferraldeschi R; Minchell LJ; Roberts SA; Tobi S; Hadfield KD; Blackhall FH; Mullamitha S; Wilson G; Valle J; Saunders M; Newman WG
    Pharmacogenomics; 2009 May; 10(5):733-9. PubMed ID: 19450125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive Value of
    Aoullay Z; Smith A; Slaoui M; El Bouchikhi I; Ghazal H; Al Idrissi N; Meddah B; Lynch KL; Cherrah Y; Wu AHB
    Genet Test Mol Biomarkers; 2023 May; 27(5):133-141. PubMed ID: 37257181
    [No Abstract]   [Full Text] [Related]  

  • 56. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
    Innocenti F; Undevia SD; Iyer L; Chen PX; Das S; Kocherginsky M; Karrison T; Janisch L; Ramírez J; Rudin CM; Vokes EE; Ratain MJ
    J Clin Oncol; 2004 Apr; 22(8):1382-8. PubMed ID: 15007088
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
    Tejpar S; Yan P; Piessevaux H; Dietrich D; Brauchli P; Klingbiel D; Fiocca R; Delorenzi M; Bosman F; Roth AD
    Eur J Cancer; 2018 Aug; 99():66-77. PubMed ID: 29909091
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
    Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
    Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
    Deeken JF; Slack R; Marshall JL
    Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
    Ramchandani RP; Wang Y; Booth BP; Ibrahim A; Johnson JR; Rahman A; Mehta M; Innocenti F; Ratain MJ; Gobburu JV
    J Clin Pharmacol; 2007 Jan; 47(1):78-86. PubMed ID: 17192505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.